***2015 – New Generic Drugs and New***

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***New Generics*** | | | | | |
| ***Generic Name*** | ***Company (ies)*** | ***Therapeutic Category*** | ***Strength(s) & Dosage Form(s)*** | ***Trade Name Equivalent*** | ***Comments/ Availability*** |
| amlodipine /valsartan | Sandoz | Antihypertensive | 5 mg/160mg, 5mg/320mg, 10mg/320mg tablets | EXFORGE | Now available |
| aripiprazole | Alembic, Hetero, Teva, Torrent | Antipsychotic / Antimanic Agent | 2mg, 5mg, 10mg, 15mg, 20mg & 30 mg tablets | ABILIFY | Launch announced by Teva |
| darifenacin | Anchen/Par | Urinary Antispasmodics | 7.5mg & 15mg extended release tablets | ENABLEX | Now available |
| esomeprazole | Ivax | Proton Pump Inhibitor | 20mg, 40mg capsules | NEXIUM | Now available |
| fluorouracil | Spear | Dermatological | 0.5% Cream | CARAC | Now available |
| glatiramer acetate | Sandoz / Momenta | Multiple Sclerosis Agent | 20mg/ml single-dosed syringe | COPAXONE | Product Name – GLATOPA. No confirmed launch date. |
| tenofovir disoproxil fumarate | Teva | Antiretroviral | 300 mg tablets | VIREAD | Available soon |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ***2015 New Drugs*** | | | | | |
| ***Trade Name (generic name)*** | ***Therapeutic Category*** | ***Strength(s) & Dosage Form(s)*** | ***Indication*** | ***Dosing*** | ***Similar Products*** |
| Corlanor (ivabradine) Amgen | Cardiovascular Agent | 5 mg \* 7.5 mg tablets | To reduce risk of hospitalization for worsening heart failure in pts with stable , symptomatic chronic heart failure with left ventricular ejection < 35% who are in sinus rhythm with resting hear rate > 70 beats per minute & either on max tolerated doses of beta blockers or have contraindication | Starting dose 5 mg twice daily. After 2 weeks of tx, adjust based on heart rate. Max dose = 7.5 mg twice daily. In pts with conduction defects or in whom bradycardia could lead to hemodynamic compromise, initiate dosing at 2.5 mg twice daily. | None |
| Cresemba (isavuconazonium sulfate) Astellas | Antifungal | 100mg capsules (186mg sulfate) & 200 mg single-dose vials (372 mg sulfate) | Treatment of invasive aspergillosis & invasive mucomycosis in pts 18 years and older | Loading dose: 372 mg isavuconazonium sulfate (200 mg) every 8 hours x 6 doses. Maintenance dose: 372 mg sulfate (200mg) daily starting 12 to 24 hours after last loading dose. | Itraconazole, NOXAFIL, voriconazole. |
| ***Late 2014 New Drugs*** | | | | | |
| Efinaconazole (Jublia) Valeant | Antifungal | 4- and 8-mL white plastic bottles | Topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes | Apply the solution once daily to clean, dry toenails at least 10 minutes after showering, bathing, or washing | None |
| ***Late 2014 New Drugs- continued*** | | | | | |
| Ledipasvir/Sofosbuvir  (Harvoni)  Gilead | Antiviral | 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet | Treatment of chronic HCV genotype 1 infection in adults | 1 tablet taken orally once daily on a regular schedule with or without food. | Numerous |
| Naloxegol (Movantik) AstraZeneca | Gastrointestinal | 12.5- and 25-mg tablets | PEGylated derivative of naloxone and acts as an opioid antagonist. Naloxegol is indicated for the treatment of opioid-induced constipation in adult patients with chronic noncancer pain | 25 mg once daily in the morning. In patients who cannot tolerate 25 mg, the daily dose can be reduced to 12.5 mg. The starting dose for patients whose CrCl is less than 60 mL/min (ie, patients with moderate, severe, or end-stage renal impairment) is 12.5 mg once daily | None |
| Netupitant/palonosetron (Akynzeo) Eisai | Gastrointestinal | Netupitant/palonosetron capsules contain 300 mg netupitant and 0.5 mg palonosetron and are supplied in a blister containing 1 capsule | Fixed combination of netupitant, a substance P/neurokinin 1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including highly emetogenic chemotherapy | Dosing with highly emetogenic chemo, including cisplatin-based chemo, is 1 capsule administered 1 hour before the start of chemo, with dexamethasone 12 mg administered orally 30 minutes before chemo on day 1 and 8 mg of dexamethasone administered orally once daily on days 2 to 4  Dosing with anthracyclines and cyclophosphamide-based chemo and chemo not considered highly emetogenic is 1 capsule approximately 1 hour before the start of chemo, with dexamethasone 12 mg administered orally 30 minutes before chemo on day 1. Administration of dexamethasone on days 2 to 4 is not necessary.7 | No other combinations  Ondansetron (Zofran); Granisetron (Kytril) |
| Pirfenidone (Esbriet) InterMune | Anti-inflammatory / antifibrotic | Each capsule contains 801 mg of medication | Treatment of idiopathic pulmonary fibrosis | Treatment is titrated over a 14-day initiation period as follows: 1 capsule 3 times a day on days 1 through 7, followed by 2 capsules 3 times a day on days 8 through 14. Thereafter, maintenance dosing is 3 capsules 3 times a day. |  |